StreetInsider.com News Articles

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 07:00:00 -0400

VERO BEACH, FL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced its participation in two upcoming investor conferences.

Sheila Gujrathi, M.D., a member of the Processa board of directors and founder and former executive chair of Vidya Therapeutics, will give a company presentation at the following:

Thursday, September 10, at 10:15 a.m. ET at the Wells Fargo 21st Annual Healthcare Conference. Register for the webcast here.

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 07:00:00 -0400

Sheila Gujrathi, M.D., a member of the Processa board of directors and founder and former executive chair of Vidya Therapeutics, will give a company presentation at the following:

Thursday, September 10, at 10:15 a.m. ET at the Wells Fargo 21st Annual Healthcare Conference. Register for the webcast here.

Form SCHEDULE 13G Processa Pharmaceuticals Filed by: Soleus Capital Master Fund, L.P.

Tue, 18 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260818/26945215.html

Form SCHEDULE 13G Processa Pharmaceuticals Filed by: Soleus Capital Master Fund, L.P.

Tue, 18 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260818/26945215.html

Form 10-Q Processa Pharmaceuticals For: Jun 30

Fri, 14 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260814/26930434.html

Form 10-Q Processa Pharmaceuticals For: Jun 30

Fri, 14 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260814/26930434.html

Form 4 Processa Pharmaceuticals For: Aug 08 Filed by: Ng George K

Tue, 11 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260811/26906129.html

Form 4 Processa Pharmaceuticals For: Aug 08 Filed by: Ng George K

Tue, 11 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260811/26906129.html

Form 8-K Processa Pharmaceuticals For: Jul 30

Tue, 04 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260804/26868103.html

Form 8-K Processa Pharmaceuticals For: Jul 30

Tue, 04 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260804/26868103.html

Form 4 Processa Pharmaceuticals For: Jul 28 Filed by: GUJRATHI SHEILA

Thu, 30 Jul 2026 21:50:00 -0400

si-local-file:///var/storage/secattach/20260730/26845271.html

Form 4 Processa Pharmaceuticals For: Jul 28 Filed by: GUJRATHI SHEILA

Thu, 30 Jul 2026 21:50:00 -0400

si-local-file:///var/storage/secattach/20260730/26845271.html

Form 3 Processa Pharmaceuticals For: Jul 28 Filed by: GUJRATHI SHEILA

Thu, 30 Jul 2026 21:46:00 -0400

si-local-file:///var/storage/secattach/20260730/26845270.html

Form 3 Processa Pharmaceuticals For: Jul 28 Filed by: GUJRATHI SHEILA

Thu, 30 Jul 2026 21:46:00 -0400

si-local-file:///var/storage/secattach/20260730/26845270.html

Form 8-K Processa Pharmaceuticals For: Jul 23

Wed, 29 Jul 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20260729/26830676.html

Form 8-K Processa Pharmaceuticals For: Jul 23

Wed, 29 Jul 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20260729/26830676.html

Processa acquires Vidya Therapeutics in $200M private placement deal

Wed, 29 Jul 2026 07:30:14 -0400

Processa Pharmaceuticals (Nasdaq: PCSA) announced the acquisition of Vidya Therapeutics, a clinical-stage biotechnology company, along with a concurrent private placement expected to raise approximately $200 million in gross proceeds.

The acquisition is structured as a stock-for-stock transaction in which Vidya's equity holders will receive a combination of 558,398 shares of Processa common stock and 142,744.100 shares of Series A non-voting convertible preferred stock, representing approximately 142.7 million shares of common stock on an as-converted basis. Following the close of both transactions, existing Processa stockholders will own approximately 0.9% of the company on a fully diluted basis, while Vidya equity holders and

Processa acquires Vidya Therapeutics in $200M private placement deal

Wed, 29 Jul 2026 07:30:14 -0400

PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA

Wed, 29 Jul 2026 07:30:00 -0400

Acquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton’s tyrosine kinase inhibitor (BTKi) designed to overcome the efficacy and safety limitations of early-generation BTKi programs
Concurrent oversubscribed private placement financing of approximately $200 million committed by a syndicate of leading healthcare institutional investors and mutual funds
Private placement proceeds are expected to fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept studies for food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS)
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA

Wed, 29 Jul 2026 07:30:00 -0400
- Acquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton’s tyrosine kinase inhibitor (BTKi) designed to overcome the efficacy and safety limitations of early-generation BTKi programs
- Concurrent oversubscribed private placement financing of approximately $200 million committed by a syndicate of leading healthcare institutional investors and mutual funds
- Private placement proceeds are expected to fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept studies for food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS)
- Form 4 Processa Pharmaceuticals For: Jul 26 Filed by: Yorke Justin W
  
  Tue, 28 Jul 2026 20:31:00 -0400
  si-local-file:///var/storage/secattach/20260728/26828706.html
  
  Form 4 Processa Pharmaceuticals For: Jul 26 Filed by: Yorke Justin W
  
  Tue, 28 Jul 2026 20:31:00 -0400
  si-local-file:///var/storage/secattach/20260728/26828706.html
  
  Form 4 Processa Pharmaceuticals For: Jul 26 Filed by: SKIBSTED RUSSELL
  
  Tue, 28 Jul 2026 20:29:00 -0400
  si-local-file:///var/storage/secattach/20260728/26828697.html
  
  Form 4 Processa Pharmaceuticals For: Jul 26 Filed by: SKIBSTED RUSSELL
  
  Tue, 28 Jul 2026 20:29:00 -0400
  si-local-file:///var/storage/secattach/20260728/26828697.html
  
  Form 4 Processa Pharmaceuticals For: Jul 26 Filed by: Pannu Geraldine
  
  Tue, 28 Jul 2026 20:28:00 -0400
  si-local-file:///var/storage/secattach/20260728/26828690.html

StreetInsider.com News Articles

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Form SCHEDULE 13G Processa Pharmaceuticals Filed by: Soleus Capital Master Fund, L.P.

Form SCHEDULE 13G Processa Pharmaceuticals Filed by: Soleus Capital Master Fund, L.P.

Form 10-Q Processa Pharmaceuticals For: Jun 30

Form 10-Q Processa Pharmaceuticals For: Jun 30

Form 4 Processa Pharmaceuticals For: Aug 08 Filed by: Ng George K

Form 4 Processa Pharmaceuticals For: Aug 08 Filed by: Ng George K

Form 8-K Processa Pharmaceuticals For: Jul 30

Form 8-K Processa Pharmaceuticals For: Jul 30

Form 4 Processa Pharmaceuticals For: Jul 28 Filed by: GUJRATHI SHEILA

Form 4 Processa Pharmaceuticals For: Jul 28 Filed by: GUJRATHI SHEILA

Form 3 Processa Pharmaceuticals For: Jul 28 Filed by: GUJRATHI SHEILA

Form 3 Processa Pharmaceuticals For: Jul 28 Filed by: GUJRATHI SHEILA

Form 8-K Processa Pharmaceuticals For: Jul 23

Form 8-K Processa Pharmaceuticals For: Jul 23

Processa acquires Vidya Therapeutics in $200M private placement deal

Processa acquires Vidya Therapeutics in $200M private placement deal

PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA

PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA

Form 4 Processa Pharmaceuticals For: Jul 26 Filed by: Yorke Justin W

Form 4 Processa Pharmaceuticals For: Jul 26 Filed by: Yorke Justin W

Form 4 Processa Pharmaceuticals For: Jul 26 Filed by: SKIBSTED RUSSELL

Form 4 Processa Pharmaceuticals For: Jul 26 Filed by: SKIBSTED RUSSELL

Form 4 Processa Pharmaceuticals For: Jul 26 Filed by: Pannu Geraldine